The goal of this clinical trial is to learn if radiofrequency ablation works to treat recurrent colorectal cancer liver metastases after surgery in adults. It will also learn about the safety of radiofrequency ablation. The main questions it aims to answer are:
Is radiofrequency ablation safe and effective in the treatment of recurrent colorectal cancer liver metastases? What medical problems do participants have when treating with radiofrequency ablation? Does radiofrequency ablation enable patients with recurrent colorectal cancer liver metastases to live longer? Researchers will compare systemic therapy combined with radiofrequency ablation to systemic therapy to see if radiofrequency ablation works to treat liver metastases better.
Participants will:
Receive systemic treatment for colorectal cancer liver metastases. Undergo (or not) radiofrequency ablation for colorectal cancer liver metastases.
Visit the hospital once every 3 months for checkups and tests.
Patients with colorectal cancer whose primary lesions have been resected or can be controlled;
Multiple confined lesions in the liver, the number of which can be defined;
The liver contains at least 2 lesions suitable for radiofrequency ablation;
The maximum diameter of the intrahepatic tumor is <5 cm;
Suffering from, but not limited to, the following serious illnesses: congestive heart failure, myocardial infarction or cerebrovascular accident, or life-threatening cardiac arrhythmia within the last 6 months;
Pregnancy or lactation. Women of childbearing potential must have a negative serum pregnancy test prior to receiving study treatment;
Known hypersensitivity to any of the intravenous imaging agents that will be used in the study;
Have portal or hepatic vein tumor infiltration/cancer embolism;